CoChat
Sign Up
Cited by 132Gastrointestinal motility and disordersInfant Health and DevelopmentGastroesophageal reflux and treatments

Alosetron, a 5‐HT 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

Open access
Houghton, Foster, Whorwell·2000·Alimentary Pharmacology & Therapeutics
DOI 10.1046/j.1365-2036.2000.00762.x
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Alosetron is a potent and selective 5‐HT 3 receptor antagonist, which has been shown to be beneficial in the treatment of female patients with non‐constipated irritable bowel syndrome. Aims: To investigate the effect of alosetron on whole gut, small bowel and colonic transit in patients with irritable bowel syndrome (Study 1) and healthy volunteers (Study 2). Subjects: Thirteen patients with irritable bowel syndrome and 12 healthy volunteers. Methods: Both studies were randomized, double‐blind, placebo‐controlled with a two‐way crossover design, in which each subject received alosetron (2 mg b.d. administered orally) or placebo for 8 days. Mean whole gut transit was determined from the excretion of radio‐opaque markers; small bowel transit was determined from rise in breath hydrogen after a meal; and colonic transit and segmental transit were evaluated from abdominal X‐ray. In addition, colonic transit was calculated by subtracting small bowel transit time from whole gut transit time. Results: Alosetron increased colonic transit time by prolonging left colonic transit in both patients with irritable bowel syndrome and controls. This resulted in a tendency for the whole gut transit to be delayed in irritable bowel syndrome patients ( P =0.128), which was confirmed in controls ( P =0.047). Conclusion: Alosetron delays colonic transit by prolonging left colonic transit. These results add to the body of evidence suggesting that alosetron should have a therapeutic role in patients with non‐constipated irritable bowel syndrome.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2000.00762.x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Drugs acting as antagonists at the 5-HT3 receptor are also licensed for IBS-D. These include alosetron and ramosetron, which slow gastrointestinal transit, reduce visceral hypersensitivity and alter rectal compliance.

    “Drugs acting as antagonists at the 5-HT 3 receptor are also licensed for IBS-D. These include alosetron and ramosetron, which slow gastrointestinal transit, reduce visceral hypersensitivity and alter rectal compliance. [231][232][233]”

    From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [231]

    The Summary reports that alosetron delayed colonic transit in IBS patients and healthy volunteers. It also describes reduced rectal sensitivity with granisetron, increased rectal compliance with ondansetron, and increased colonic—not rectal—compliance with alosetron. The paper does not establish that alosetron or ramosetron was licensed for IBS-D, or report these effects for ramosetron; the Discussion instead calls alosetron a suitable treatment candidate. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • 5-HT3 antagonists slow gastrointestinal transit and reduce visceral hypersensitivity.

    “5-HT3 antagonists and eluxadoline slow gastrointestinal transit and reduce visceral hypersensitivity”

    From Irritable bowel syndrome (2020) · cites this paper as [119]

  • Eluxadoline slows gastrointestinal transit and reduces visceral hypersensitivity.

    “5-HT3 antagonists and eluxadoline slow gastrointestinal transit and reduce visceral hypersensitivity”

    From Irritable bowel syndrome (2020) · cites this paper as [119]

    The Summary reports that alosetron, a 5-HT3 antagonist, delays colonic transit and discusses sensitivity findings for 5-HT3 antagonists. The cited paper does not address eluxadoline or its effects on transit or visceral hypersensitivity (searched: eluxadoline, visceral hypersensitivity, transit). (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 6

  1. Drossman DA, Sandler RS, McKee DC, Lovitz AJ. Bowel pat- terns among subjects not seeking health care. Use of a ques- tionnaire to identify a population with bowel dysfunction. Gastroenterology 1982; 83: 529±34.
  2. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Dig Dis Sci 1993; 38: 1569±80.
  3. Mayer EA, Munakata J, Mertz H, Lembo T, Bernstein CN. Visceral hyperalgesia and irritable bowel syndrome. In: Geb- hert GF, ed. Visceral Pain, Progress in Pain Research and Management, Vol 5. Seattle, USA: IASP Press, 1995: 429±68.
  4. Thompson WG, Creed F, Drossman DA, Heaton KW, Mazzacca G. Functional bowel disease and functional abdominal pain. Working team report. Gastroenterol Int 1992; 5: 75±91.
  5. Lubke HJ, Warskulat C, Licht G, Frieling T, Euck P, Weinbeck M. 5-HT 3 receptors have minimal effects on normal gut function. Gastroenterology 1988; 94: A271(Abstract).
  6. Von der Ohe MR, Camilleri M, Kvols LK. A 5-HT 3 antagonist corrects the postprandial colonic hypertonic response in car- cinoid diarrhoea. Gastroenterology 1994; 106: 1184±9.

Cited by

Sorted by citations

Related

Authors
Houghton, Foster, & Whorwell
Affiliations
Manchester University NHS Foundation Trust (GB)
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2000-06
Volume
14
Issue
6
Pages
775-782
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
DOI
10.1046/j.1365-2036.2000.00762.x
OpenAlex
W2049197933
Cited by
132
References
34
Citations by year
2026: 2 · 2025: 2 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 8 · 2020: 2 · 2019: 5 · 2018: 3 · 2016: 4 · 2015: 3 · 2014: 8 · 2013: 2 · 2012: 3
FWCI
10.66
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 571 d)
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Health Professions › Pharmacy › Infant Health and Development
  • Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
Keywords
alosetron, 5-HT3 receptor antagonists, irritable bowel syndrome, colonic transit, whole gut transit, small intestinal transit, radio-opaque markers, breath hydrogen, abdominal radiography
MeSH terms
Adult, Carbolines, Colon, Colonic Diseases, Functional, Double-Blind Method, Female, Gastrointestinal Transit, Humans, Intestine, Small, Male, Middle Aged, Serotonin Antagonists, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review